CN107011313B - 取代桂皮酰胺衍生物在制备抗焦虑药物中的应用 - Google Patents
取代桂皮酰胺衍生物在制备抗焦虑药物中的应用 Download PDFInfo
- Publication number
- CN107011313B CN107011313B CN201710038281.3A CN201710038281A CN107011313B CN 107011313 B CN107011313 B CN 107011313B CN 201710038281 A CN201710038281 A CN 201710038281A CN 107011313 B CN107011313 B CN 107011313B
- Authority
- CN
- China
- Prior art keywords
- iii
- anxiety
- substituted
- application
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002249 anxiolytic agent Substances 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title claims description 27
- 230000000949 anxiolytic effect Effects 0.000 title claims description 19
- 229940079593 drug Drugs 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title description 10
- APEJMQOBVMLION-VOTSOKGWSA-N trans-cinnamamide Chemical class NC(=O)\C=C\C1=CC=CC=C1 APEJMQOBVMLION-VOTSOKGWSA-N 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 45
- APEJMQOBVMLION-UHFFFAOYSA-N cinnamamide Chemical class NC(=O)C=CC1=CC=CC=C1 APEJMQOBVMLION-UHFFFAOYSA-N 0.000 claims abstract description 22
- 208000019901 Anxiety disease Diseases 0.000 claims description 24
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims description 12
- 230000036506 anxiety Effects 0.000 claims description 11
- 230000001154 acute effect Effects 0.000 claims description 5
- JCJGVPPUOCEWAK-UHFFFAOYSA-N 5-[3,4-dimethoxy-5-(trifluoromethyl)phenyl]-N-(2-methylpropyl)penta-2,4-dienamide Chemical compound C(C(C)C)NC(C=CC=CC1=CC(=C(C(=C1)C(F)(F)F)OC)OC)=O JCJGVPPUOCEWAK-UHFFFAOYSA-N 0.000 claims description 4
- MAKZWAJRIQDMMP-UHFFFAOYSA-N C(C(C)C)NC(CCC1=CC(=C(C(=C1)C(F)(F)F)O)O)=O Chemical compound C(C(C)C)NC(CCC1=CC(=C(C(=C1)C(F)(F)F)O)O)=O MAKZWAJRIQDMMP-UHFFFAOYSA-N 0.000 claims description 4
- -1 N-substituted piperazine Chemical class 0.000 abstract description 14
- 125000000217 alkyl group Chemical group 0.000 abstract description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract description 6
- 150000003254 radicals Chemical class 0.000 abstract description 5
- 125000003386 piperidinyl group Chemical group 0.000 abstract description 4
- 150000003839 salts Chemical class 0.000 abstract description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 24
- 241000700159 Rattus Species 0.000 description 23
- 150000002430 hydrocarbons Chemical group 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 229930195733 hydrocarbon Natural products 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000003651 drinking water Substances 0.000 description 10
- 235000020188 drinking water Nutrition 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000004215 Carbon black (E152) Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000019906 panic disease Diseases 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 230000035939 shock Effects 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229940049706 benzodiazepine Drugs 0.000 description 4
- 229960003529 diazepam Drugs 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 208000037870 generalized anxiety Diseases 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 3
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IAVYOLZXHINLBW-UHFFFAOYSA-N C(C(C)C)NC(C1=CC(=C(C(=C1)C(F)(F)F)O)O)=O Chemical compound C(C(C)C)NC(C1=CC(=C(C(=C1)C(F)(F)F)O)O)=O IAVYOLZXHINLBW-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004300 GABA-A Receptors Human genes 0.000 description 2
- 108090000839 GABA-A Receptors Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- LYGLNNNTUIWBBN-UHFFFAOYSA-N n-(2-methylpropyl)-7-(trifluoromethyl)-1,3-benzodioxole-5-carboxamide Chemical compound FC(F)(F)C1=CC(C(=O)NCC(C)C)=CC2=C1OCO2 LYGLNNNTUIWBBN-UHFFFAOYSA-N 0.000 description 2
- 208000020470 nervous system symptom Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001671 psychotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IMOLAGKJZFODRK-UHFFFAOYSA-N 2-phenylprop-2-enamide Chemical compound NC(=O)C(=C)C1=CC=CC=C1 IMOLAGKJZFODRK-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 208000024470 urgency of urination Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
本发明提供了一种取代桂皮酰胺衍生物在制备抗焦虑药物中的应用,所述的取代桂皮酰胺衍生物为式(Ⅰ)结构的化合物或其可药用盐作为药物活性成分,具体如下:式中:R1为‑H、‑OH、‑F、‑Cl、‑Br、‑I、‑OCH3、‑OCF3、‑OCHF2、‑OCH2F、‑CF3、‑CHF2、‑CH2F、‑CH3、‑CH3CH2、‑CF3CH2、‑CN、‑NO2、‑NH2或‑COOR5;R2为H、C1‑C10直链烃基、C3‑C10支链烃基、C3‑C10环烃基、C1‑C10羟烷基或N‑取代哌嗪衍生基团;或R2为与相邻的X形成四氢吡咯基、哌啶基或环己亚胺基的基团。
Description
技术领域:
本发明涉及一种药物新用途,特别涉及一种取代桂皮酰胺衍生物在制备抗焦虑药物中的应用。
背景技术:
焦虑症,又称为焦虑性神经症,是神经症这一大类疾病中最常见的一种,以焦虑情绪体验为主要特征。可分为慢性焦虑(广泛性焦虑)和急性焦虑发作(惊恐障碍)两种形式。主要表现为:无明确客观对象的紧张担心,坐立不安,还有植物神经症状(心悸、手抖、出汗、尿频等)。
具体的,
慢性焦虑,又称广泛性焦虑,在没有明显诱因的情况下,患者经常出现过分担心、紧张害怕,但紧张害怕常常没有明确的对象和内容。主要表现为:(1)情绪症状:紧张不安、提心吊胆,恐惧、害怕、忧虑。(2)植物神经症状:头晕、胸闷、心慌、呼吸急促、口干、尿频、尿急、出汗、震颤等躯体方面的症状。(3)运动性不安:坐立不安,坐卧不宁,烦躁,很难静下心来。
急性焦虑发作,又称惊恐发作、惊恐障碍,在正常的日常生活环境中,并没有恐惧性情境时,患者突然出现极端恐惧的紧张心理,伴有濒死感或失控感,同时有明显的植物神经系统症状,主要表现为:(1)濒死感或失控感:突然出现极度恐惧的心理,体验到濒死感或失控感。(2)植物神经系统症状同时出现:如胸闷、心慌、呼吸困难、出汗、全身发抖等。(3)一般持续几分钟到数小时:发作开始突然,发作时意识清楚。
在当今社会,伴随着人们生活节奏的加快和工作压力增大,社会竞争日益激烈,焦虑症的患病率逐年上升。
焦虑症的治疗,通常采用心理治疗和药物治疗,其中:
心理治疗,找出生活中的压力源,避开压力,学习放松技巧,减轻压力;
药物治疗,用抗焦虑药物去平静脑中过度活跃的部分,较为典型的药物苯二氮卓类药物(BDZ),其抗焦虑作用强,起效快,但长期服用有成瘾性、耐药性及戒断反应等副作用;三环类抗抑郁药(TCAs)对广泛性焦虑有良好疗效,但有较强的抗胆碱能副作用和心脏毒性作用,限制了它们的应用;其他用于抗焦虑的药物也或多或少的存在起效缓慢、药物间相互作用和不良反应等问题。以上副作用常令患者十分顾虑,这种担忧反而加重焦虑,或被迫放弃治疗。停药反应更是医生面临的难中之难。
因此,亟需一种可以有效治疗焦虑,且副作用少的药物。本发明桂皮酰胺衍生物在单次经口给药后能快速跨过血脑屏障从而发挥其抗焦虑效果。
桂皮酰胺,又称苯丙烯酰胺,肉桂酰胺,3-苯基丙烯酰胺,其取代桂皮酰胺衍生物曾经在CN102850317A(申请号为CN201210123842.7)和CN104513172A(申请号为CN201410504555.X)中公开了一系列取代的桂皮酰胺衍生物及其制备方法,动物实验研究发现,取代桂皮酰胺衍生物具有明显的抗抑郁活性。
未见到取代的桂皮酰胺衍生物在抗焦虑方面的报道。
本发明涉及取代桂皮酰胺衍生物在制备抗焦虑药物中的应用。本发明通过考察取代桂皮酰胺衍生物对小鼠在高架十字迷宫实验中进入开臂次数和在开臂停留时间的影响,以及对大鼠在饮水冲突实验中惩罚期饮水次数的影响,验证其在抗焦虑方面的作用,实验证明取代桂皮酰胺衍生物中有17种化合物在给药7天后能在不同程度上增加小鼠进入开臂的次数,并延长小鼠在开臂停留的时间,且能明显增加大鼠在饮水冲突实验中惩罚期饮水次数,从而证明取代桂皮酰胺衍生物可以开发为抗焦虑药物。
发明内容:
本发明涉及取代桂皮酰胺衍生物的新应用。
具体的,本发明提供了取代桂皮酰胺衍生物在制备抗焦虑药物中的应用。
其中,所述焦虑是指慢性焦虑(广泛性焦虑)或者急性焦虑(惊恐发作、惊恐障碍)。
所述的取代桂皮酰胺衍生物为式(Ⅰ)结构的化合物或其可药用盐作为药物活性成分,具体如下:
式中:
R1为-H、-OH、-F、-Cl、-Br、-I、-OCH3、-OCF3、-OCHF2、-OCH2F、-CF3、-CHF2、-CH2F、-CH3、-CH3CH2、-CF3CH2、-CN、-NO2、-NH2或-COOR5;
R2为H、C1-C10直链烃基、C3-C10支链烃基、C3-C10环烃基、C1-C10羟烷基或N-取代哌嗪衍生基团;或R2为与相邻的X形成四氢吡咯基、哌啶基或环己亚胺基的基团;
R3或R4各自独立地为H、OH、OR5、F、Cl、Br、I、C1-C10直链烃基、C3-C10支链烃基、CF3、CHF2、CH2F、NO2、NH2、OCF3、OCHF2、OCH2F、OOCR5或COOR5;
或,R3与R4相连形成-OCH2O-、-OCH2CH2O-;
其中,R5为C1-C10直链烃基、C3-C10支链烃基、C3-C10环烃基、C1-C10羟烷基;
n为1、2或3,-(C2-C3)n-单元最少含有一个碳碳单键或者一个碳碳双键;
X为=O、=S、H、SH或SR6;
Y为N或NR6、O或S;
R6为H、C1-C10直链烃、C3-C10支链烃、C3-C10环烃或C6-C10芳香烃;
优选的,所述取代桂皮酰胺衍生物如式(Ⅱ)所示,
其中,
R1为-H、-OH、-F、-Cl、-Br、-I、-OCH3、-OCF3、-OCHF2、-OCH2F、-CF3、-CHF2、-CH2F、-CH3、-CH3CH2、-CF3CH2、-CN、-NO2、-NH2或-COOR5;
R2为H、C1-C10直链烃、C3-C10支链烃、C3-C10环烃、C6-C10芳香烃或C1-C10烷基醇或N-取代哌嗪衍生物,或R2为与相邻的X形成四氢吡咯基、哌啶基或环己亚胺基的基团。
R5为C1-C10直链烃基、C3-C10支链烃基、C3-C10环烃基、C1-C10羟烷基;
n为1、2或3,-(C2-C3)n-单元最少含有一个碳碳单键或者一个碳碳双键;
X为=O、=S、H、SH或SR6;
Y为N或NR6、O或S;其中R6为H、C1-C10直链烃、C3-C10支链烃、C3-C10环烃或C6-C10芳香烃;
或优选的,所述取代桂皮酰胺衍生物如式(Ⅲ)所示,
其中,
R3为H、OH、OR5、F、Cl、Br、I、C1-C10直链烃基、C3-C10支链烃基、CF3、CHF2、CH2F、NO2、NH2、OCF3、OCHF2、OCH2F、OOCR5或COOR5;
R4为H、OH、OR5、F、Cl、Br、I、C1-C10直链烃基、C3-C10支链烃基、CF3、CHF2、CH2F、NO2、NH2、OCF3、OCHF2、OCH2F、OOCR5或COOR5;
R5为C1-C10直链烃基、C3-C10支链烃基、C3-C10环烃基、C1-C10羟烷基;
n为1、2或3,-(C2-C3)n-单元最少含有一个碳碳单键或者一个碳碳双键;
X为N或NH;
R2为H、C1-C10直链烃、C3-C10支链烃、C3-C10环烃、C6-C10芳香烃或C1-C10烷基醇或N-取代哌嗪衍生物,或R2为与相邻的X形成四氢吡咯基、哌啶基或环己亚胺基的基团。
本发明的化合物或其可药用酸加成盐,特别优选的是以下化合物:
5′-碘-3′,4′-次甲二氧基桂皮酸异丁基酰胺(Ⅱ-3)
5′-氯-3′,4′-次甲二氧基桂皮酸异丁基酰胺(Ⅱ-4)
5′-三氟甲基-3′,4′-次甲二氧基桂皮酸异丁基酰胺(Ⅱ-5)
5′-三氟甲基-3′,4′-次甲二氧基桂皮酸哌啶基酰胺(Ⅱ-10)
3-(5′-三氟甲基-3′,4′-次甲二氧基苯基)-丙酸异丁基酰胺(Ⅱ-11)
5-三氟甲基-3,4-次甲二氧基苯甲酸异丁基酰胺(Ⅱ-12)
(E)-N-(4-甲基哌嗪基)-5-(5′-三氟甲基-3′,4′-次甲二氧基苯基)-1-戊烯酰胺盐酸盐(Ⅱ-13)
(2E,4E)-N-异丁基-7-(5′-三氟甲基-3′,4′-次甲二氧基苯基)-2,4-庚二烯酰胺
(Ⅱ-14)
(2E,4E)-N-(4-甲基哌嗪基)-7-(5′-三氟甲基-3′,4′-次甲二氧基苯基)-2,4-庚二烯酰胺胺盐酸盐(Ⅱ-15)
N-甲基-(5′-三氟甲基-3′,4′-次甲二氧基)-苯丙胺盐酸盐(Ⅱ-16)
3′,4′-二甲氧基-5′-三氟甲基-桂皮酸异丁基酰胺(Ⅲ-2)
3′-羟基-4′-甲氧基-5′-三氟甲基-桂皮酸异丁基酰胺(Ⅲ-4)
3′,4′-二羟基-5′-三氟甲基-桂皮酸异丁基酰胺(Ⅲ-7)
3′,4′-二羟基-5′-三氟甲基-桂皮酰基哌啶(Ⅲ-9)
3-(3′,4′-二羟基-5′-三氟甲基苯基)-丙酸异丁基酰胺(Ⅲ-10)
3,4-二羟基-5-三氟甲基-苯甲酸异丁基酰胺(Ⅲ-11)
5-(5′-三氟甲基-3′,4′-二甲氧基苯基)戊二烯酸异丁基酰胺(Ⅲ-13)
本发明所述的应用,其中所述药物可以是含有本发明化合物或其药用盐的药物组合物,可以被制备成任何一种可药用的剂型,这些剂型包括:片剂、胶囊剂、颗粒剂、丸剂、散剂、膏剂、丹剂、粉剂、溶液剂、注射剂、栓剂、喷雾剂、滴剂、贴剂。
本发明的药物组合物,其口服给药的制剂可含有常用的赋形剂,诸如粘合剂、填充剂、稀释剂、压片剂、润滑剂、崩解剂、着色剂、调味剂和湿润剂。适用的填充剂包括淀粉、蔗糖、纤维素、甘露糖醇、乳糖和其它类似的填充剂。适宜的崩解剂包括淀粉、聚乙烯吡咯烷酮和淀粉衍生物,例如羟基乙酸淀粉钠。适宜的润滑剂包括,例如硬脂酸镁。可通过混合,填充,压片等常用的方法制备固体口服组合物。进行反复混合可使活性物质分布在整个使用大量填充剂的那些组合物中;常用的辅料成分包括:甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素C、EDTA二钠、EDTA钙钠,一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、吐温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁等。
本发明的制剂在使用时根据况确定用法用量,可以每日服1-5次。
本发明提供的取代桂皮酰胺衍生物的新应用具有以下优点:
1、发明人发现本发明提供的化合物能够改善焦虑症,并发现该衍生物能快速透过血脑屏障,具有起效快的特点。同时,对焦虑导致的睡眠障碍也有较明显的改善作用。
2、经动物自主活动评估证实,本发明提供的化合物抗焦虑活性不是化合物对动物活动度抑制作用的继发结果;此外以5g/kg的剂量灌服该化合物,动物未见明显不良反应,说明其安全性高,耐受性好。
3、传统的中枢苯二氮卓类抗焦虑药物如地西泮具有镇静、肌肉松弛等副作用,从而限制了其在临床中的应用。
经利用Western-blot技术检测相关基因的表达变化,发现本发明所述的17种化合物可调节线粒体自噬相关基因的表达,可能为外周型苯二氮卓受体的结合性配体。外周型苯二氮卓受体与本发明所述的化合物结合后,能刺激线粒体分泌类固醇,调节生物的行为,表现出明显的抗焦虑作用,且无镇静、肌松等副作用。
所以,相比于传统的中枢苯二氮卓类抗焦虑药物,本发明所述的化合物可能具有起效快,副反应少且不易产生耐受性等优势。
具体实施方式
以下通过实施例进一步说明本发明。
化合物Ⅱ-3、Ⅱ-4、Ⅱ-5、Ⅱ-10、Ⅱ-11、Ⅱ-12及其制备方法见CN201210123842.7(公开号为CN102850317A);
化合物Ⅲ-2、Ⅲ-4、Ⅲ-7、Ⅲ-9、Ⅲ-10、Ⅲ-11、Ⅲ-13及其制备方法见CN201410504555.X(公开号为CN104513172A);
化合物Ⅱ-13、Ⅱ-14、Ⅱ-15、Ⅱ-16的制备方法见实施例1-4。
实施例1:(E)-N-(4-甲基哌嗪基)-5-(5′-三氟甲基-3′,4′-次甲二氧基苯基)-1-戊烯酰胺盐酸盐(Ⅱ-13)
步骤1:将化合物1(1.53g,4.0mmol)置于100ml的单口瓶中,加入15ml氯仿溶解,再将化合物2(1g,4.0mmol)加到反应体系中,室温搅拌反应14h;TLC监测(展开剂PE:EA=5:1)显示反应完全;然后将反应物直接浓缩得粗产物化合物3,经硅胶柱色谱纯化(PE:EA=5:1)后,得到1.1g白色固体化合物3,收率78.87%。
步骤2:把化合物3(0.3g,0.87mmol)溶于5ml二氯甲烷中,降温至0℃;将三氟乙酸(1ml)滴加到反应体系中,然后将反应体系升温的室温下反应;1h后TLC显示原料反应完毕,把反应体系直接浓缩,得到化合物4白色固体0.21g(84%)。
步骤3:把化合物4(0.48g,1.66mmol)、N-甲基哌嗪(0.5g,5mmol)、DIPEA(0.43g,3.34mmol)、加到二氯甲烷中,氮气置换三次,然后加入HATU(0.95g,2.5mmol)室温下搅拌6h;反应体系经水洗涤,有机相干燥浓缩得到粗品,经硅胶柱色谱纯化后得到400mg无色油状物;然后用2ml的二氧六环溶解,再加入4ml的二氧六环的盐酸溶液,室温下搅拌30min,浓缩干燥得到43mg化合物Ⅱ-13(65%)。
1H NMR(DMSO,400MHz):δ11.28-11.27.00(1H,NH,br),7.11(1H,s),6.94(1H,s),6.70(1H,d,J=15.2Hz),6.50(1H,d,J=15.2Hz),6.17(2H,s),4.33(2H,br),3.42-3.20(6H,br),2.75(4H,s),2.51(3H,s);
ESI-MS:371.1[M+H]+
实施例2:(2E,4E)-N-异丁基-7-(5′-三氟甲基-3′,4′-次甲二氧基苯基)-2,4-庚二烯酰胺(Ⅱ-14)
步骤1:50ml三口瓶中加入化合物5(650mg,2.6mmol)、20ml无水四氢呋喃、氢氧化锂(326mg,7.8mmol),N2保护下加热至70℃反应1小时。将化合物1(0.76g,2.0mmol)溶于10ml无水四氢呋喃中,0.5小时内将其滴入反应瓶中。反应液于70℃反应10小时。薄层色谱检测,反应完全后停止加热。将反应液旋转蒸发浓缩至干,加入20ml蒸馏水使固体溶解。向上述溶液中慢慢滴加2N盐酸至pH 2.0,继续搅拌1小时,析出淡黄色固体,减压抽滤收集固体,真空干燥得到化合物6(400mg,65%)。
步骤2:把物料6(400mg,1.4mmol)、EDCI(410mg,2.14mmol)、异丁胺(310mg,4.2mmol)溶到20ml二氯甲烷中,室温搅拌反应6后TLC显示原料反应完,然后把反应体系直接缩干,粗产品经硅胶柱色谱纯化(正己烷:乙酸乙酯=3:1)后,得到270mg白色固体Ⅱ-14(52%)。
1H NMR(DMSO,400MHz):δ7.18(1H,dd,J1=10.8Hz,J2=4.4Hz),6.80(1H,d,J=5.6Hz),6.11(2H,m),6.06(2H,s),5.76(1H,d,J=15.2Hz),5.46(1H,s),3.17(2H,t,J=6.0Hz),2.68(2H,t,J=7.6Hz),2.44(2H,m),1.80(1H,m),0.94(3H,s),0.92(3H,s);
ESI-MS:370.1[M+H]+
实施例3:(2E,4E)-N-(4-甲基哌嗪基)-7-(5′-三氟甲基-3′,4′-次甲二氧基苯基)-2,4-庚二烯酰胺盐酸盐(Ⅱ-15)
化合物6(0.52g,1.66mmol)、N-甲基哌嗪(0.5g,5mmol)、DIPEA(0.43g,3.34mmol)加到二氯甲烷中,然后加入HATU(0.95g,2.5mmol)室温下搅拌6h;反应体系经水洗涤,有机相干燥浓缩得到粗品,经硅胶柱色谱纯化后得到350mg无色油状物;然后用2ml的二氧六环溶解,再加入4ml的二氧六环的盐酸溶液,室温下搅拌30min,浓缩干燥得到370mg化合物Ⅱ-15(53%)。
1H NMR(MeOD,400MHz):δ7.25(1H,dd,J1=10.8Hz,J2=4.4Hz),6.96(1H,s),6.87(1H,s),6.48(1H,d,J=14.8Hz),6.31(1H,dd,J1=10.8Hz,J2=4.4Hz),6.21(1H,m),6.10(2H,s),4.87(2H,br),3.77-3.50(3H,br),3.40-3.10(3H,br),3.15(3H,s),2.76(2H,t,J=7.2Hz),2.50(2H,t,J=7.2Hz);
ESI-MS:397.1[M+H]+
实施例4:N-甲基-(5′-三氟甲基-3′,4′-次甲二氧基)-苯丙胺盐酸盐(Ⅱ-16)
50ml三口瓶中加入化合物1(650mg,2.6mmol)、甲胺溶液(0.4ml,5.1mmol),氰基硼氢化钠(430mg,5.2mmol)加入至20ml无水甲醇中,室温反应6小时。反应液加入50ml水,乙酸乙酯(50ml×2)萃取后,浓缩有机相得粗产物,粗产物经硅胶柱色谱(正己烷:乙酸乙酯=1:1)纯化后得320mg油状物;
然后用2ml的二氧六环溶解,再加入4ml的二氧六环的盐酸溶液,室温下搅拌30min,浓缩干燥得到340mg化合物Ⅱ-16(47%)。
1H NMR(D2O,400MHz):δ6.93(1H,s),6.92(1H,s),6.01(2H,s),2.93(2H,t,J=8.0Hz),2.62(2H,t,J=8.0Hz),2.61(3H,s),1.90(2H,m);
ESI-MS:263.2[M+H]+
实施例5:滴丸制剂的制备
取化合物Ⅱ-3、Ⅱ-4、Ⅱ-5、Ⅱ-10、Ⅱ-11、Ⅱ-12、Ⅱ-13、Ⅱ-14、Ⅱ-15、Ⅱ-16,Ⅲ-2、Ⅲ-4、Ⅲ-7、Ⅲ-9、Ⅲ-10、Ⅲ-11、或Ⅲ-13 0.5g,与10.5g聚乙二醇-6000混合均匀,加热熔融,化料后移至滴丸滴灌中,药液滴至6-8℃液体石蜡中,除油,制得滴丸500粒。
实施例6:注射剂
取化合物Ⅱ-3、Ⅱ-4、Ⅱ-5、Ⅱ-10、Ⅱ-11、Ⅱ-12、Ⅱ-13、Ⅱ-14、Ⅱ-15、Ⅱ-16,Ⅲ-2、Ⅲ-4、Ⅲ-7、Ⅲ-9、Ⅲ-10、Ⅲ-11、或Ⅲ-13 0.5g,以及葡萄糖4.5g、硫代硫酸钠0.9g和蒸馏水1ml,上述组分混合均匀后,冷冻干燥,分装500支,即得。
以下通过实验数据说明本发明的有益效果:
实验例1:小鼠高架十字迷宫实验
(一)实验材料
1、待测样品
取代桂皮酰胺衍生物如化合物Ⅱ-3、Ⅱ-4、Ⅱ-5、Ⅱ-10、Ⅱ-11、Ⅱ-12、Ⅱ-13、Ⅱ-14、Ⅱ-15,Ⅱ-16,Ⅲ-2、Ⅲ-4、Ⅲ-7、Ⅲ-9、Ⅲ-10、Ⅲ-11、Ⅲ-13:由天士力控股集团有限公司研究院中药所提供。
样品处理:向2wt%的吐温80水溶液中加入化合物Ⅱ-3、Ⅱ-4、Ⅱ-5、Ⅱ-10、Ⅱ-11、Ⅱ-12、Ⅱ-13、Ⅱ-14、Ⅱ-15,Ⅱ-16,Ⅲ-2、Ⅲ-4、Ⅲ-7、Ⅲ-9、Ⅲ-10、Ⅲ-11、Ⅲ-13,分别将上述化合物配制成浓度为0.5mg/ml的溶液。
地西泮,生产厂家:北京益民药业有限公司,规格:2.5mg/片,国药准字H11020898,临用时通过2wt%的吐温80水溶液配制成含有0.075mg/ml药品的溶液。
2、实验动物
SPF级ICR雄性小鼠,购买自北京维通利华实验动物技术有限公司,实验动物生产许可证:SCXK(京)2012-0001。
饲养条件:屏障动物房饲养,温度20-25℃,相对湿度40%-60%,每笼12只,自由饮食,饲料为灭菌全价鼠专用饲料,该饲料由北京华埠康生物科技股份有限公司提供;每日更换垫料。
3、实验仪器
高架十字迷宫:北京新天地科技有限责任公司。
(二)实验方法
取247只ICR小鼠,雄性,鼠龄6-8周,体重18-22g,适应性喂养1周。然后,将小鼠按体重随机平均分入19个组中,按表1中所列药物和剂量每日灌胃给药1次,连续给药7天。在第7天给药20min后进行高架十字迷宫实验。
小鼠高架十字迷宫(EPM),由两个相对的敞开臂(openarms,50cm×10cm)和两个相对的闭臂(en-closedarms,50cm×10cm×40cm)组成,闭臂上部未封顶,迷宫中央为10cm×10cm的开阔部,迷宫离地面50cm。实验于13:00~18:00安静环境下进行。
各给药组连续给药7天,受试物于末次给药后20min,阳性药地西泮于末次给药后60min进行高架十字迷宫实验,将每只小鼠放入一个60cm×60cm×35cm塑料盒中,让其熟悉环境5min后再置于迷宫中央,记录5min内小鼠分别进入开臂和闭臂的次数以及在两臂内的滞留时间,计算各组小鼠进入开臂的次数(open-armsentries,OE)和在开臂停留时间(open-armstime,OT)分别占进入两臂总次数和在两臂停留总时间的百分比(OE%和OT%)。
(三)实验统计
采用SPSS 11.5软件进行分析,数据以x±S表示,用方差分析比较组间差异的显著性,P<0.05为有显著性差异。
(四)实验结果
本实验评价了本发明17个化合物对小鼠在高架十字迷宫实验中进入开臂次数和在开臂停留时间的影响。
表1各化合物对小鼠进入开臂次数及在开臂停留时间的影响
注:与溶剂对照组相比,*p<0.05,**p<0.01
表1实验结果显示:将本发明化合物Ⅱ-3、Ⅱ-4、Ⅱ-5、Ⅱ-10、Ⅱ-11、Ⅱ-12、Ⅱ-13、Ⅱ-14、Ⅱ-15,Ⅱ-16,Ⅲ-2、Ⅲ-4、Ⅲ-7、Ⅲ-9、Ⅲ-10、Ⅲ-11、Ⅲ-13,以10mg/kg剂量灌胃给药1周后,与溶剂对照组相比,均能延长小鼠进入开臂的次数,并延长在其在开臂停留的时间,上述结果在统计学上的差异显著(p<0.05,p<0.01)。
实验结论:在高架十字迷宫实验中,以10mg/kg的剂量,将本发明所述的17种化合物给药7天均能在不同程度上增加高架十字迷宫实验中小鼠进入开臂的次数,并延长小鼠在开臂停留的时间。
实验结果可以证明:本发明所述的17种化合物具有显著的抗焦虑活性。
实验例2:大鼠饮水冲突实验
(一)实验材料
1、待测样品
取代桂皮酰胺衍生物如化合物Ⅱ-3、Ⅱ-4、Ⅱ-5、Ⅱ-10、Ⅱ-11、Ⅱ-12、Ⅱ-13、Ⅱ-14、Ⅱ-15,Ⅱ-16,Ⅲ-2、Ⅲ-4、Ⅲ-7、Ⅲ-9、Ⅲ-10、Ⅲ-11、Ⅲ-13:由天士力控股集团有限公司研究院中药所提供。
样品处理:向2wt%的吐温80水溶液中加入化合物Ⅱ-3、Ⅱ-4、Ⅱ-5、Ⅱ-10、Ⅱ-11、Ⅱ-12、Ⅱ-13、Ⅱ-14、Ⅱ-15,Ⅱ-16,Ⅲ-2、Ⅲ-4、Ⅲ-7、Ⅲ-9、Ⅲ-10、Ⅲ-11、Ⅲ-13,分别将上述化合物配制成浓度为0.5mg/ml的溶液。
地西泮,生产厂家:北京益民药业有限公司,规格:2.5mg/片,国药准字H11020898,临用时通过2wt%的吐温80水溶液配制成含有0.01mg/ml药品的溶液。
2、实验动物
SPF级雄性SD大鼠,购买自北京维通利华实验动物技术有限公司,实验动物生产许可证:SCXK(京)2012-0001。
饲养条件:屏障动物房饲养,温度20-25℃,相对湿度40%-60%,每笼6只,自由饮食,饲料为灭菌全价鼠专用饲料,该饲料由北京华埠康生物科技股份有限公司提供;每日更换垫料。
3、实验仪器
Vogel test(吮水电击)焦虑测试系统,型号:LE100-25,美国哈佛仪器公司生产。
(二)实验方法
230只SD大鼠,雄性,体重180-220g,适应性喂养1周后按体重随机分19组,每组12-13只,按表2中所列药物和剂量每日灌胃给药1次,连续给药10天,末次给药前48h禁水,第9d进行非惩罚性饮水训练;第10d所有组末次灌胃0.5h后,进行惩罚实验测试。
第一阶段,非惩罚饮水训练:将大鼠禁水24h后单个置于操作箱,让其充分探究,直到发现瓶嘴并开始舔水,计数器自动记录无电击条件下大鼠3min的舔水次数设置条件:电击强度0mA),淘汰舔水少于300次的大鼠。第二阶段,惩罚实验:上述未被淘汰的大鼠继续禁水24h(共48h)后置于操作箱。大鼠能很快找到瓶嘴并开始舔水,舔够20次仪器自动开始计时并给予一次电击(舔水与电击次数之比为20:1),电击强度为0.3mA,持续2s,但是大鼠可通过脱离瓶嘴来控制受电击时间的长短。记录惩罚期(3min)大鼠的舔水次数。
Vogel饮水冲突模型观察指标:惩罚期内大鼠的舔水次数。
(三)实验统计
采用SPSS 11.5软件进行分析,数据以x±S表示,用方差分析比较组间差异的显著性,P<0.05为有显著性差异。
(四)实验结果
本实验评价了本发明17个化合物对大鼠饮水冲突实验中惩罚期大鼠舔水次数的影响。
表2各化合物对惩罚期大鼠舔水次数的影响
注:与溶剂对照组相比,*p<0.05,**p<0.01
表2实验结果显示:将本发明化合物Ⅱ-3、Ⅱ-4、Ⅱ-5、Ⅱ-10、Ⅱ-11、Ⅱ-12、Ⅱ-13、Ⅱ-14、Ⅱ-15,Ⅱ-16,Ⅲ-2、Ⅲ-4、Ⅲ-7、Ⅲ-9、Ⅲ-10、Ⅲ-11、Ⅲ-13,以5mg/kg剂量灌胃给药10d后,与溶剂对照组相比,均能增加大鼠惩罚期饮水次数,上述结果在统计学上的差异显著(p<0.05,p<0.01)。
实验结论:大鼠饮水冲突实验中,以5mg/kg的剂量,将本发明所述的17种化合物给药10天均能在不同程度上增加大鼠惩罚期的饮水次数。
实验结果可以证明:本发明所述的17种化合物具有抗焦虑活性。
Claims (4)
3.根据权利要求1所述的应用,其特征在于,所述焦虑是指慢性焦虑或者急性焦虑。
4.根据权利要求2所述的应用,其特征在于,所述焦虑是指慢性焦虑或者急性焦虑。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016100531809 | 2016-01-27 | ||
CN201610053180 | 2016-01-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107011313A CN107011313A (zh) | 2017-08-04 |
CN107011313B true CN107011313B (zh) | 2021-11-30 |
Family
ID=59398770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710038281.3A Active CN107011313B (zh) | 2016-01-27 | 2017-01-19 | 取代桂皮酰胺衍生物在制备抗焦虑药物中的应用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10874636B2 (zh) |
EP (1) | EP3409664B1 (zh) |
JP (1) | JP6847116B2 (zh) |
KR (1) | KR20180103846A (zh) |
CN (1) | CN107011313B (zh) |
AU (1) | AU2017213007B2 (zh) |
CA (1) | CA3007870C (zh) |
IL (1) | IL260068B (zh) |
RU (1) | RU2738648C2 (zh) |
WO (1) | WO2017129061A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021097027A1 (en) * | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Seladelpar for use in the treatment of alcoholic liver disease |
US20240109855A1 (en) * | 2021-01-14 | 2024-04-04 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Anti-quorum sensing, anti-biofilm, and inflammation attenuating compounds, compositions, and methods of using same |
AU2022282252A1 (en) | 2021-05-28 | 2023-10-05 | Tasly Pharmaceutical Group Co., Ltd. | Antidepressant and anxiolytic substituted cinnamamide compound |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE697104A (zh) * | 1965-09-02 | 1967-10-17 | ||
JP2000086603A (ja) * | 1998-07-15 | 2000-03-28 | Yoshitomi Pharmaceut Ind Ltd | 桂皮酸アミド誘導体および3―フェニルプロピオン酸アミド誘導体 |
CN102850317A (zh) * | 2011-06-27 | 2013-01-02 | 天士力制药集团股份有限公司 | 一种取代桂皮酰胺衍生物、制备方法及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1463997A (en) * | 1995-12-22 | 1997-07-17 | Acea Pharmaceuticals, Inc. | Subtype-selective nmda receptor ligands and the use thereof |
EP1392644A1 (en) | 2001-05-31 | 2004-03-03 | Bristol-Myers Squibb Company | Cinnamide derivatives as kcnq potassium channel modulators |
US6900354B2 (en) | 2002-07-15 | 2005-05-31 | Hoffman-La Roche Inc. | 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives |
DE102004039373A1 (de) | 2004-08-12 | 2006-02-23 | Grünenthal GmbH | Para-Alkyl-substituierte N-(4-Hydroxy-3-methoxy-benzyl)-zimtsäureamide und deren Verwendung zur Herstellung von Arzneimitteln |
US20070049578A1 (en) * | 2005-08-24 | 2007-03-01 | Astrazeneca Ab | Cinnamamide compounds as metabotropic glutamate receptor antagonists |
TW200817315A (en) * | 2006-06-16 | 2008-04-16 | Sanol Arznei Schwarz Gmbh | Entacapone-derivatives |
EP2519511B1 (en) * | 2009-12-30 | 2015-12-16 | Universität Wien | Novel piperine derivatives as gaba-a receptors modulators |
CN102775394B (zh) * | 2011-05-12 | 2016-03-09 | 天士力制药集团股份有限公司 | 一种酰胺类化合物及其制备方法和应用 |
GB201116335D0 (en) * | 2011-09-21 | 2011-11-02 | Novaremed Ltd | A method of treating or preventing affective disorders |
CN104513172B (zh) * | 2013-09-30 | 2018-02-02 | 天士力医药集团股份有限公司 | 含有三氟甲基的酰胺生物碱、制备方法及其药物用途 |
CN105085308B (zh) * | 2015-08-07 | 2017-05-10 | 天津中医药大学 | 菖蒲酰胺类化合物及其制备方法与应用 |
-
2017
- 2017-01-19 CN CN201710038281.3A patent/CN107011313B/zh active Active
- 2017-01-20 RU RU2018122135A patent/RU2738648C2/ru active
- 2017-01-20 CA CA3007870A patent/CA3007870C/en active Active
- 2017-01-20 JP JP2018533742A patent/JP6847116B2/ja active Active
- 2017-01-20 KR KR1020187016535A patent/KR20180103846A/ko not_active Application Discontinuation
- 2017-01-20 WO PCT/CN2017/071898 patent/WO2017129061A1/zh active Application Filing
- 2017-01-20 US US16/073,507 patent/US10874636B2/en active Active
- 2017-01-20 EP EP17743676.3A patent/EP3409664B1/en active Active
- 2017-01-20 AU AU2017213007A patent/AU2017213007B2/en active Active
-
2018
- 2018-06-17 IL IL260068A patent/IL260068B/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE697104A (zh) * | 1965-09-02 | 1967-10-17 | ||
US3431302A (en) * | 1965-09-02 | 1969-03-04 | Lilly Co Eli | Cinnamic acid derivatives |
JP2000086603A (ja) * | 1998-07-15 | 2000-03-28 | Yoshitomi Pharmaceut Ind Ltd | 桂皮酸アミド誘導体および3―フェニルプロピオン酸アミド誘導体 |
CN102850317A (zh) * | 2011-06-27 | 2013-01-02 | 天士力制药集团股份有限公司 | 一种取代桂皮酰胺衍生物、制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
JP2019503368A (ja) | 2019-02-07 |
EP3409664A1 (en) | 2018-12-05 |
AU2017213007A1 (en) | 2018-06-07 |
RU2738648C2 (ru) | 2020-12-15 |
IL260068B (en) | 2021-06-30 |
IL260068A (en) | 2018-07-31 |
WO2017129061A1 (zh) | 2017-08-03 |
JP6847116B2 (ja) | 2021-03-24 |
AU2017213007B2 (en) | 2021-01-21 |
KR20180103846A (ko) | 2018-09-19 |
EP3409664B1 (en) | 2021-01-06 |
RU2018122135A (ru) | 2019-12-23 |
RU2018122135A3 (zh) | 2020-02-25 |
US10874636B2 (en) | 2020-12-29 |
CA3007870A1 (en) | 2017-08-03 |
EP3409664A4 (en) | 2019-08-28 |
US20190046500A1 (en) | 2019-02-14 |
CN107011313A (zh) | 2017-08-04 |
CA3007870C (en) | 2024-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10071989B2 (en) | Substituted cinnamamide derivative, preparation method and use thereof | |
WO2013060258A1 (zh) | 伸筋草碱a-c、其制法和其药物组合物与用途 | |
CN107011313B (zh) | 取代桂皮酰胺衍生物在制备抗焦虑药物中的应用 | |
CN106866733A (zh) | 左旋美普他酚前药及其制备方法和用途 | |
JP2014532669A (ja) | N−ベンジルアニリン誘導体及びその使用 | |
WO2011133212A1 (en) | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders | |
CN111518058B (zh) | 一种噁噻嗪类化合物及其用途 | |
WO2019011350A1 (zh) | 芬乐胺晶g型、制备方法和其组合物与用途 | |
PT2053050E (pt) | Di-hidrocalcona idêntica a aspalatina e método para a sua preparação | |
WO2014180321A1 (zh) | 间苯三酚类衍生物及其在治疗神经退行性疾病中的用途 | |
CN115536607A (zh) | 一种杂原子取代的芳香类化合物及其制备方法和用途 | |
CN104513172B (zh) | 含有三氟甲基的酰胺生物碱、制备方法及其药物用途 | |
CN109293566A (zh) | 酰胺类衍生物及其应用 | |
KR950002151B1 (ko) | 뇌 허혈성 병을 수반하는 질환 치료제 | |
CN112691102A (zh) | 黄芩素在防治帕金森病/帕金森综合征抑郁症状中的应用 | |
KR102078433B1 (ko) | 변비증의 예방 또는 치료약 | |
CN112094255B (zh) | 一种灯盏花乙素苷元衍生物、其制备方法与应用 | |
CN116987091A (zh) | 用于治疗癫痫发作疾病的药物及其制备方法 | |
CN115400109A (zh) | 酪胺及其衍生物在制备治疗抑郁症药物中的应用 | |
CN109456259A (zh) | 酰胺类衍生物及其应用 | |
CN113491680A (zh) | 邻苯二酚及衍生物在制备用于治疗睡眠障碍药物中的用途 | |
NZ618801B2 (en) | Substituted cinnamamide derivative, preparation method and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Applicant after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Applicant before: Tasly Pharmaceutical Group Co., Ltd. |
|
CB02 | Change of applicant information | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |